Keyphrases
Advanced Ovarian Cancer
76%
Adverse Events
15%
Anemia
7%
Anticancer Activity
7%
Area under the Concentration-time Curve
15%
Cancer Model
7%
Cancer Risk
7%
Carboplatin
23%
Carboplatin-paclitaxel
76%
Chemotherapy Administration
7%
Common Terminology Criteria for Adverse Events (CTCAE)
7%
Diabetic Patients
7%
Diarrhea
7%
Dose Level
15%
Dose-limiting Toxicity
15%
Drug Metabolism
23%
Epidemiological Study
7%
Epithelial Ovarian Cancer
7%
Fixed-dose Combination
7%
Hypomagnesemia
7%
Kidney Transplant Recipients
76%
Leukopenia
7%
Liquid Chromatography-high Resolution Mass Spectrometry (LC-HRMS)
7%
Living Kidney Donor
76%
Metabolic Genotype
15%
Metabolic Profiling
7%
Metabolism Study
15%
Metformin
76%
Metformin Use
7%
Metoprolol
76%
Neoadjuvant
7%
Ovarian Cancer
15%
Paclitaxel
15%
Paclitaxel Chemotherapy
76%
Pharmacogenetics
15%
Pharmacogenomics
76%
Pharmacokinetic Analysis
7%
Pharmacokinetic Interaction
7%
Pharmacokinetics
7%
Phase I Study
76%
Plasma Parameters
7%
Plasma Samples
7%
Recommended Phase 2 Dose
46%
Serum Samples
7%
Single Center
7%
Single-dose Treatment
7%
Targeted Agents
7%
Therapeutic Range
7%
Thrombocytopenia
7%
Treatment Cycle
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
13%
Anemia
6%
Benzoic Acid
7%
Cancer Model
6%
Carboplatin
76%
Carboxylate
7%
Chemotherapy
76%
Ciclosporin
15%
Clinical Trial
7%
Cohort Study
23%
Comorbidity
15%
CYP2D6
7%
Diabetes Mellitus
6%
Diarrhea
6%
Drug Metabolism
100%
Drug Metabolite
15%
Drug Metabolizing Enzyme
15%
Drug-Drug Interaction
15%
Glutathione
15%
Hypomagnesemia
6%
Leukopenia
6%
Malignant Neoplasm
6%
Metformin
76%
Methyl Group
7%
Metoprolol
76%
Normal Human
7%
Ovary Cancer
20%
Ovary Carcinoma
76%
Paclitaxel
76%
Pharmacogenetics
23%
Pharmacogenomics
15%
Pharmacokinetics
20%
Thrombocytopenia
6%